SAN DIEGO, Aug. 25 Amylin Pharmaceuticals, Inc.(Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) will Web cast aconference call on Tuesday, August 26 at 5:00 p.m. ET/2:00 p.m. PT to discussthe recent FDA advisory on BYETTA(R) (exenatide) injection. Leading the callfor Amylin will be Daniel M. Bradbury, Amylin's President and Chief ExecutiveOfficer and Orville G. Kolterman, M.D., Amylin's Senior Vice President ofResearch and Development. Leading the call for Lilly will be Donald Therasse,M.D., Lilly's Vice President of Global Patient Safety.
The call will be Web cast live through Amylin's corporate Web site and arecording will be made available following the close of the call. To accessthe Web cast, please log on to http://www.amylin.com approximately fifteenminutes prior to the call to register, download and install any necessaryaudio software. For those without access to the Internet, the live call may beaccessed by phone by calling (866) 814-1915 (domestic) or (703) 639-1359(international), passcode 1277182. A replay of the call will also beavailable by phone through September 26, 2008 beginning approximately one hourafter the close of the call and can be accessed at (888) 266-2081 (domestic)or (703) 925-2533 (international), passcode 1277182.
About Amylin and Lilly
Amylin Pharmaceuticals is a biopharmaceutical company committed toimproving lives through the discovery, development and commercialization ofinnovative medicines. Amylin has developed and gained approval for twofirst-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)injection and BYETTA(R) (exenatide) injection. Amylin's research anddevelopment activities leverage the company's expertise in metabolism todevelop potential therapies to treat diabetes and obesity. Amylin isheadquartered in San Diego, California with over 2,000 employees nationwide.Further information on Amylin Pharmaceuticals is available athttp://www.amylin.com.
Through a long-standing commitment to diabetes care, Lilly providespatients with breakthrough treatments that enable them to live longer,healthier and fuller lives. Since 1923, Lilly has been the industry leader inpioneering therapies to help health care professionals improve the lives ofpeople with diabetes, and research continues on innovative medicines toaddress the unmet needs of patients. For more information about Lilly'scurrent diabetes products visit http://www.lillydiabetes.com.
Lilly, a leading innovation-driven corporation, is developing a growingportfolio of first-in-class and best-in-class pharmaceutical products byapplying the latest research from its own worldwide laboratories and fromcollaborations with eminent scientific organizations. Headquartered inIndianapolis, Indiana, Lilly provides answers -- through medicines andinformation -- for some of the world's most urgent medical needs. Additionalinformation about Lilly is available at http://www.lilly.com.
SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company